Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for polyneuropathy, inflammatory demyelinating, chronic has been reported in the published literature.
No approved treatments are currently available for polyneuropathy, inflammatory demyelinating, chronic. An additional 4 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for polyneuropathy, inflammatory demyelinating, chronic, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for polyneuropathy, inflammatory demyelinating, chronic. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
3 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE3. Research is primarily industry-sponsored.
200 publications have been identified in PubMed for polyneuropathy, inflammatory demyelinating, chronic. Research spans Review / Meta-Analysis (35%), Epidemiology / Natural History (18%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 67 |
Data assembled from 4 of 12 sources · Last updated Nov 4, 2026, 5:38 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
nipocalimab | nipocalimab | Janssen Research & Development, LLC | 2021 | — | Designated |
recombinant humanized IgG4 monoclonal antibody against pHERV-W Envelope protein | recombinant humanized IgG4 monoclonal antibody against pHERV-W Envelope protein | GeNeuro S.A. | 2018 | — | Designated |
recombinant multimerized human IgG1 Fc | recombinant multimerized human IgG1 Fc | Gliknik Inc. | 2015 | — | Designated |
Hizentra | Immune Globulin Subcutaneous (Human), 20% Liquid | CSL Behring | 2014 | 2025 | Designated (drug approved for other indication) |
Gene therapy approaches for polyneuropathy, inflammatory demyelinating, chronic have been reported in the published literature.
3 trials found
Disease patterns and progression | 34 | 18% |
Clinical study results | 24 | 13% |
Patient case studies | 22 | 12% |
Testing and diagnosis research | 20 | 10% |
Laboratory research | 11 | 6% |
Other research | 9 | 5% |
New treatment approaches | 4 | 2% |
Sgodzai M (2026). [PMID: 40817835](https://pubmed.ncbi.nlm.nih.gov/40817835/). *Brain*. [Clinical Trial Publication]
Ginsberg M (2026). [PMID: 42124394](https://pubmed.ncbi.nlm.nih.gov/42124394/). *Muscle Nerve*. [Diagnostic / Biomarker]
Luijten LWG (2026). [PMID: 41526144](https://pubmed.ncbi.nlm.nih.gov/41526144/). *Handb Clin Neurol*. [Review / Meta-Analysis]
Hubsch A (2026). [PMID: 41252088](https://pubmed.ncbi.nlm.nih.gov/41252088/). *Neurol Ther*. [Epidemiology / Natural History]
Niu J (2026). [PMID: 41980868](https://pubmed.ncbi.nlm.nih.gov/41980868/). *Muscle Nerve*. [Clinical Trial Publication]
Park JS (2026). [PMID: 41517807](https://pubmed.ncbi.nlm.nih.gov/41517807/). *J Clin Neurol*. [Other]
Shimizu F (2026). [PMID: 41596734](https://pubmed.ncbi.nlm.nih.gov/41596734/). *Int J Mol Sci*. [Epidemiology / Natural History]
Xiao J (2026). [PMID: 41360045](https://pubmed.ncbi.nlm.nih.gov/41360045/). *J Neurol Sci*. [Basic Science / Preclinical]
Yoshikawa M (2026). [PMID: 41850835](https://pubmed.ncbi.nlm.nih.gov/41850835/). *Intern Med*. [Epidemiology / Natural History]
Blum TC (2026). [PMID: 41982060](https://pubmed.ncbi.nlm.nih.gov/41982060/). *Muscle Nerve*. [Epidemiology / Natural History]
AI-curated news mentioning polyneuropathy, inflammatory demyelinating, chronic
Updated Oct 22, 2026
New research identifies data-driven subtypes of chronic inflammatory demyelinating polyneuropathy (CIDP), challenging existing classification systems. This study highlights the clinical heterogeneity of CIDP, which may impact future diagnostic and treatment approaches.
A recent study discusses the use of matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy (CIDP). The authors emphasize the need for improved methodologies to interpret current evidence and enhance future studies in this area.
A recent study identifies newly developing IgM anti-GD1a/GD1b ganglioside monoclonal gammopathy in a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This discovery may provide insights into the pathophysiology of CIDP and potential therapeutic targets.
Sanofi has discontinued its Phase 3 study for a complement inhibitor drug targeting chronic inflammatory demyelinating polyneuropathy due to underwhelming efficacy results. This decision reflects broader challenges within the drug class, impacting future development prospects.
A personal story highlights how a diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) motivated the author to engage in advocacy efforts. The narrative emphasizes the importance of community support and awareness for rare diseases.